New hope for rare kidney disease: eculizumab trial shows promise in china
NCT ID NCT05876351
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the drug eculizumab in 25 children and adults in China with a rare kidney condition called atypical hemolytic uremic syndrome (aHUS). The goal was to see if the drug could stop blood clots and improve kidney function. All participants received eculizumab intravenously, and researchers measured blood cell counts and kidney markers to assess response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- eculizumab
- What this could lead to
- If successful, this could confirm eculizumab as a safe and effective treatment for aHUS in Chinese patients, helping control the disease and prevent kidney damage.
- What could go wrong
- This is a small, single-arm study with no placebo group, so results may not be definitive. Eculizumab requires lifelong treatment and carries risks like serious infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL HEMOLYTIC UREMIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Beijing, 100034, China
-
Research Site
Beijing, 100045, China
-
Research Site
Changsha, 410007, China
-
Research Site
Qingdao, 110016, China
-
Research Site
Taiyuan, 030012, China
-
Research Site
Wuhan, 430030, China